Advaxis to Present at NYC MedTech Program
Advaxis, Inc ., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Thomas A. Moore, Chairman & CEO of Advaxis, will present at the NYC MedTech Program, a medical technology and life science forum founded by John Lieberman CPA, Managing Director of Perelson Weiner LLP. The Program will be held on Tuesday, December 4, 2012 at the offices of Kaye Scholer LLP in New York City. More information can be found at www.nycmedtech.com. 
About NYC MedTech
NYC Medtech is a professional platform that assists many different collaborators in the life science, biotech, device and pharma industries have successful outcomes. This unique program not only brings together companies and investors but all people that are involved from reporters, scientists, academia, trade organizations, international partners, etc. The NYC Medtech program introduces invited participants with relevant timely introductions whether through the website, email or the personal touch at the NYC Medtech Forum. NYC Medtech was created and founded by John R. Lieberman at Perelson Weiner, LLP, along with Wendy Brown of Merrill Lynch and is sponsored by Kaye Scholer LLP. John Lieberman is also the founder of Frankfurt MedTech (www.frankfurtmedtech.de ), the Frankfurt based sister platform focused on enhancing collaboration between German and American medical companies.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the World Vaccine Congress website .
Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 ongoing clinical trials that are open to enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute , Cancer Research – UK , the Wistar Institute , the University of Pennsylvania , the University of British Columbia , the Karolinska Institutet , and others. For more information please visit: advaxis.com  | Facebook  | twitter  | LinkedIn 
This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at www.sec.gov . The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.